Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1104000

Prognostic value of circulating Bcl-2 and anti- p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)


Sirotković-Skerlev, Maja; Dedić Plavetić, Natalija; Sedlić, Filip; Kuna, Sanja Kusačić; Vrbanec, Damir; Belev, Borislav; Pleština, Stjepko; Kovač, Zdenko; Kulić, Ana
Prognostic value of circulating Bcl-2 and anti- p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years) // Cancer Biomarkers, 22 (2020), 1-10 doi:10.3233/cbm-201497 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1104000 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Prognostic value of circulating Bcl-2 and anti- p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)

Autori
Sirotković-Skerlev, Maja ; Dedić Plavetić, Natalija ; Sedlić, Filip ; Kuna, Sanja Kusačić ; Vrbanec, Damir ; Belev, Borislav ; Pleština, Stjepko ; Kovač, Zdenko ; Kulić, Ana

Izvornik
Cancer Biomarkers (1574-0153) 22 (2020); 1-10

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Bcl-2 ; Breast cancer ; ELISA ; anti-p53 antibodies ; survival

Sažetak
Background: Apoptosis inhibition is a major tumorigenic factor. Bcl-2 dysregulation and TP53 mutation status, which may correlate with autoantibody generation, contribute to impaired apoptosis. Objective: This study aimed to investigate the prognostic value of circulating Bcl-2 and anti- p53 antibodies (p53Abs) in a 17.5- year follow- up of breast cancer patients. We also analyzed the correlations of Bcl-2 and p53Abs with various clinicopathological parameters in order to assess their impact on tumor aggressiveness. Methods: Serum Bcl-2 and p53Abs levels were analyzed by the enzyme- linked immunosorbent assay (ELISA) in 82 patients with invasive breast cancer and twenty individuals without malignancy. Results: Serum Bcl-2 and p53Abs levels in breast cancer patients were significantly higher than those in controls. Patients with high levels of Bcl-2 (cut-off 200 U/ml) had a poorer prognosis (17.5-year survival) than those with lower Bcl- 2 values. In combined analysis the subgroup of patients with elevated p53Abs (cut-off 15 U/ml) and elevated Bcl-2 (cut-offs 124 U/ml and 200 U/ml) had the worse prognosis in 17.5-year survival. In correlation analysis p53Abs and Bcl-2 were associated with unfavorable clinicopathological parameters. Conclusions: Our results suggest that breast cancer patients with high serum levels of p53Abs and Bcl-2 present an especially unfavorable group in a long follow-up.

Izvorni jezik
Engleski

Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Zagreb,
Sveučilište Jurja Dobrile u Puli

Poveznice na cjeloviti tekst rada:

doi content.iospress.com

Citiraj ovu publikaciju:

Sirotković-Skerlev, Maja; Dedić Plavetić, Natalija; Sedlić, Filip; Kuna, Sanja Kusačić; Vrbanec, Damir; Belev, Borislav; Pleština, Stjepko; Kovač, Zdenko; Kulić, Ana
Prognostic value of circulating Bcl-2 and anti- p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years) // Cancer Biomarkers, 22 (2020), 1-10 doi:10.3233/cbm-201497 (međunarodna recenzija, članak, znanstveni)
Sirotković-Skerlev, M., Dedić Plavetić, N., Sedlić, F., Kuna, S., Vrbanec, D., Belev, B., Pleština, S., Kovač, Z. & Kulić, A. (2020) Prognostic value of circulating Bcl-2 and anti- p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years). Cancer Biomarkers, 22, 1-10 doi:10.3233/cbm-201497.
@article{article, author = {Sirotkovi\'{c}-Skerlev, Maja and Dedi\'{c} Plaveti\'{c}, Natalija and Sedli\'{c}, Filip and Kuna, Sanja Kusa\v{c}i\'{c} and Vrbanec, Damir and Belev, Borislav and Ple\v{s}tina, Stjepko and Kova\v{c}, Zdenko and Kuli\'{c}, Ana}, year = {2020}, pages = {1-10}, DOI = {10.3233/cbm-201497}, keywords = {Bcl-2, Breast cancer, ELISA, anti-p53 antibodies, survival}, journal = {Cancer Biomarkers}, doi = {10.3233/cbm-201497}, volume = {22}, issn = {1574-0153}, title = {Prognostic value of circulating Bcl-2 and anti- p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)}, keyword = {Bcl-2, Breast cancer, ELISA, anti-p53 antibodies, survival} }
@article{article, author = {Sirotkovi\'{c}-Skerlev, Maja and Dedi\'{c} Plaveti\'{c}, Natalija and Sedli\'{c}, Filip and Kuna, Sanja Kusa\v{c}i\'{c} and Vrbanec, Damir and Belev, Borislav and Ple\v{s}tina, Stjepko and Kova\v{c}, Zdenko and Kuli\'{c}, Ana}, year = {2020}, pages = {1-10}, DOI = {10.3233/cbm-201497}, keywords = {Bcl-2, Breast cancer, ELISA, anti-p53 antibodies, survival}, journal = {Cancer Biomarkers}, doi = {10.3233/cbm-201497}, volume = {22}, issn = {1574-0153}, title = {Prognostic value of circulating Bcl-2 and anti- p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)}, keyword = {Bcl-2, Breast cancer, ELISA, anti-p53 antibodies, survival} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font